An inverse head & shoulders pattern formed in the charts of Intellia, a company developing CRISPR gene-editing therapy. While CRISPR has not been approved to begin human trials in the US, it has already been tested on over 80 patients in China.
Target: $31 (previous closing high), or long term hold
Stop: $18 - $20
Target: $31 (previous closing high), or long term hold
Stop: $18 - $20
评论:
Note: 2 other companies also developing CRISPR-Cas9 tech are CRSP and EDIT. Their stocks have skyrocketed the past month. It is advisable to wait for a correction before taking a position on them.
交易结束：到达目标:
It wasn't a straightforward journey, but got there on time anyway! I hope everyone reading took profits at $31 (or even higher)